Suchkov S V, Gabibov A G, Alekberova Z S, Gnuchev N V
Ter Arkh. 2001;73(10):58-65.
To evaluate occurrence of DNA-abzymes with catalytic (DNA-hydrolysing) and cytotoxic properties in patients with systemic lupus erythematosus (SLE) for examination of clinical value of DNA-abzymes in diagnosis of autoimmune syndrome and apoptosis level in different variants of immunopathology.
The study group consisted of patients with verified SLE diagnosis (n = 120). They were compared to 72 patients with rheumatoid arthritis (RA), 82 patients with scleroderma systematica (SS), 60 patients with discoid lupus erythematosus (DLE), 88 patients with focal scleroderma (FS) and 198 autoimmune uveitis (AU) patients. 128 donors served control. Catalytic and cytotoxic activity of DNA-abzymes were determined by methods of molecular biology and enzymology. All the patients were examined for blood levels of IgG, IgM and IgA, anti-DNA, anti-Sm and other IgG-autoantibodies, CIC titers, phagocyting activity, content of main D-cell subpopulations. Key immunoregulatory indices were also estimated.
DNA-abzymes were detected more often in SLE and RA patients. In SLE, catalytic and cytotoxic activities of DNA-abzymes reached their maximum. There was a correlation with leading clinicoimmunological signs of SLE. The disease was most severe with apparent immunopathology in patients with maximal catalytic and cytotoxic activity of DNA-abzymes. With lowering cytotoxic activity of DNA-abzymes more patients demonstrate low SLE activity without severe organic lesions and alleviated symptoms of immunopathology.
An important role of DNA-abzymes in pathogenesis of SLE is shown. They are also valuable tools in diagnosis of various clinicoimmunological variants of the disease.
评估系统性红斑狼疮（SLE）患者中具有催化（DNA水解）和细胞毒性特性的DNA酶的发生情况，以检验DNA酶在自身免疫综合征诊断及不同免疫病理学变体中细胞凋亡水平方面的临床价值。
研究组由确诊为SLE的患者（n = 120）组成。将他们与72例类风湿关节炎（RA）患者、82例系统性硬皮病（SS）患者、60例盘状红斑狼疮（DLE）患者、88例局限性硬皮病（FS）患者和198例自身免疫性葡萄膜炎（AU）患者进行比较。128名献血者作为对照。采用分子生物学和酶学方法测定DNA酶的催化和细胞毒性活性。对所有患者检测血液中IgG、IgM和IgA、抗DNA、抗Sm及其他IgG自身抗体水平、循环免疫复合物（CIC）滴度、吞噬活性、主要D细胞亚群含量。还评估了关键免疫调节指标。
SLE和RA患者中更常检测到DNA酶。在SLE中，DNA酶的催化和细胞毒性活性达到最大值。与SLE的主要临床免疫指标存在相关性。DNA酶催化和细胞毒性活性最高的患者，疾病最为严重，伴有明显的免疫病理学改变。随着DNA酶细胞毒性活性降低，更多患者表现出SLE低活动度，无严重器质性病变，免疫病理学症状减轻。
显示了DNA酶在SLE发病机制中的重要作用。它们也是诊断该疾病各种临床免疫变体的有价值工具。
